Extended Data Fig. 4: Mutations identification and personalized vaccine design. | Nature Biotechnology

Extended Data Fig. 4: Mutations identification and personalized vaccine design.

From: A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy

Extended Data Fig. 4

a) Number of actionable SMs identified with NeoDisc’s default mode in NSCLC1-Tissue and NSCLC1-PEC samples, compared to the gene panel. The total number of SMs per sample is shown with bars on the left. Distribution of the mutations across samples is shown with the top bars, connected dots highlighting in which sample(s) they were identified. b) Top-10 long neoantigen peptide sequences designed by NeoDisc based on short peptide predictions and hotspot annotation. Sorted (top to bottom) HLA-I and -II predicted neoantigens considered for the design of the long peptide sequence are displayed below the long peptide sequence in dark blue and yellow, respectively. The connected dots indicate which allele(s) the short HLA-I/II peptides are predicted to bind.

Back to article page